ecopipam Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ecopipam (development codes SCH-39166, EBS-101, and PSYRX-101) is an experimental drug that acts as a selective dopamine D1/D5 receptor antagonist, with little affinity for either dopamine D2-like or 5-HT2 receptors.   Wikipedia

Chemistry

  • SMILES: CN1CCc2cc(Cl)c(O)cc2[C@@H]3[C@@H]1CCc4ccccc34
  • InChIKey: DMJWENQHWZZWDF-PKOBYXMFSA-N
  • Mol. Mass: 313.83
  • ALogP: 3.98
  • ChEMBL Molecule:
    ecopipam  
More Chemistry

Pharmacology

Alternative names

5h-benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, trans-(-)- | 6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-n-methyl-5h-benzo(d)naphtho-(2,1b)azepine | ecopipam | sch39166 | sch 39166 | sch-39166

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Adolescent (Phase 2)

Childhood-Onset Fluency Disorder (Phase 2/Phase 3)

Communication Disorders (Phase 2/Phase 3)

Drug Interactions (Phase 1)

Gambling (Phase 2)

Healthy Volunteers (Phase 1)

Language Disorders (Phase 2/Phase 3)

Lesch-Nyhan Syndrome (Phase 3)

Pediatrics (Phase 2)

Restless Legs Syndrome (Phase 1/Phase 2)

Self-Injurious Behavior (Phase 3)

Speech Disorders (Phase 2/Phase 3)

Stuttering (Phase 2/Phase 3)

Tourette Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue